Bank Of America Corp Nuvation Bio Inc. Transaction History

Bank Of America Corp

$1.12 Trillion
Q2 2024

A detailed history of Bank Of America Corp transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Bank Of America Corp holds 323,661 shares of NUVB stock, worth $938,616. This represents 0.0% of its overall portfolio holdings.

Number of Shares

323,661

Previous 365,326 11.4%

Holding current value

$938,616

Previous $1.33 Million 28.89%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.58 - $3.69 $107,495 - $153,743	-41,665 Reduced 11.4%	323,661 $945,000
Q1 2024 May 15, 2024	SELL	$1.46 - $3.97 $171,760 - $467,046	-117,644 Reduced 24.36%	365,326 $1.33 Million
Q4 2023 Feb 14, 2024	BUY	$0.96 - $1.53 $206,088 - $328,454	214,676 Added 80.02%	482,970 $729,000
Q2 2023 Aug 14, 2023	SELL	$1.56 - $1.84 $373,086 - $440,050	-239,158 Reduced 47.13%	268,294 $482,000
Q1 2023 May 12, 2023	BUY	$1.6 - $2.48 $323,625 - $501,619	202,266 Added 66.28%	507,452 $842,000
Q4 2022 Feb 10, 2023	BUY	$1.68 - $2.5 $169,239 - $251,845	100,738 Added 49.27%	305,186 $585,000
Q3 2022 Nov 14, 2022	BUY	$0.29 - $4.04 $20,499 - $285,583	70,689 Added 52.85%	204,448 $457,000
Q2 2022 Aug 12, 2022	BUY	$3.24 - $5.85 $270,063 - $487,615	83,353 Added 165.36%	133,759 $433,000
Q1 2022 May 16, 2022	SELL	$4.6 - $8.83 $4,853 - $9,315	-1,055 Reduced 2.05%	50,406 $265,000
Q4 2021 Feb 08, 2022	BUY	$7.75 - $10.05 $274,063 - $355,398	35,363 Added 219.67%	51,461 $437,000
Q3 2021 Nov 15, 2021	SELL	$7.78 - $10.0 $165,745 - $213,040	-21,304 Reduced 56.96%	16,098 $160,000
Q2 2021 Sep 13, 2021	BUY	$9.22 - $14.48 $344,846 - $541,580	37,402 New	37,402 $348,000

Others Institutions Holding NUVB

# of Institutions

151

Shares Held

123M

Call Options Held

9.7K

Put Options Held

6.5K

View Full List

About Nuvation Bio Inc.

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $630M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

More about NUVB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Nuvation Bio Inc. Transaction History